Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2992-2998

  Galizia, Gennaro ^a   De Vita, Ferdinando ^a   Lieto, Eva ^a   Zamboli, Anna ^a   Morgillo, Floriana ^a   Castellano, Paolo ^a   Mabilia, Andrea ^a   Auricchio, Annamaria ^a   Renda, Andrea ^b   Ciardiello, Fortunato ^a   Orditura, Michele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Colorectal cancer; Conversion chemotherapy; Liver metastasis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG EFFICACY; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; MALE; ONCOGENE K RAS; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84892425261     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2795     Document Type: Article

References (31)

1. Poston GJ, Adam R, Alberts S, et al: OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 23: 7125-7134, 2005.
2. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J and Bouvier AM: Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244: 254-259, 2006.
3. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H and Cohen SJ: Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5: 108-113, 2005.
4. Nordlinger B, Van Cutsem E, Rougier P, et al: Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 43: 2037-2045, 2007.
5. Cook AD, Single R and McCahill LE: Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol 12: 637-645, 2005.
6. Nordlinger B, Vauthey JN, Poston G, Benoist S, Rougier P and Van Cutsem E: The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer 9: 212-218, 2010.
7. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
8. Geva R, Prenen H, Topal B, Aerts R, Vannoote J and Van Cutsem E: Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies. J Surg Oncol 102: 937-945, 2010.
9. Galizia G, Lieto E, Orditura M, et al: First line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg 143: 352-358, 2008.
10. Galizia G, Castellano P, Pinto M, et al: Radiofrequency-assisted liver resection with a comb-shaped bipolar device versus clamp crushing: a clinical study. Surg Innov 19: 407-414, 2012.
11. Grothey A, Sargent D, Goldberg RM and Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214, 2004.
12. Van Cutsem E, Rivera F, Berry S, et al: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20: 1842-1847, 2009.
13. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019, 2011.
14. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546, 2011.
15. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705, 2010.
16. Mitry E, Fields AL, Bleiberg H, et al: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26: 4906-4911, 2008.
17. Nordlinger B, Sorbye H, Glimelius B, et al: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371: 1007-1016, 2008.
18. Folprecht G, Grothey A, Alberts S, Raab HR and Köhne CH: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16: 1311-1319, 2005.
19. Masi G, Vasile E, Loupakis F, et al: Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 103: 21-30, 2011.
20. Folprecht G, Gruenberger T, Bechstein WO, et al: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11: 38-47, 2010.
21. Klinger M, Tamandl D, Eipeldauer S, et al: Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 17: 2059-2065, 2010.
22. Masi G, Loupakis F, Salvatore L, et al: Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 11: 845-852, 2010.
23. Wong R, Cunningham D, Barbachano Y, et al: A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 22: 2042-2048, 2011.
24. Bertolini F, Malavasi N, Scarabelli L, et al: FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer 104: 1079-1084, 2011.
25. Adam R, Wicherts DA, de Haas RJ, et al: Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 26: 1635-1641, 2008.
26. Goèré D, Gaujoux S, Deschamp F, et al: Patients operated on for initially unresectable colorectal liver metastases with missing metastases experience a favorable long-term outcome. Ann Surg 254: 114-118, 2011.
27. Cleary JM, Tanabe KT, Lauwers GY and Zhu AX: Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist 14: 1095-1105, 2009.
28. Welsh FK, Tilney HS, Tekkis PP, John TG and Rees M: Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 96: 1037-1042, 2007.
29. Pessaux P, Panaro F, Casnedi S, et al: Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. Eur J Surg Oncol 36: 575-582, 2010.
30. Robertson DJ, Stukel TA, Gottlieb DJ, Sutherland JM and Fisher ES: Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer 115: 752-759, 2009.
31. Rees M, Tekkis PP, Welsh FK, O'Rourke T and John TG: Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247: 125-135, 2008.